RxDoctor Payments DataLook up a doctor →

John Bruno, MD

Urology · Danbury, CTNPI 1447378401

Payments from drug & device makers

$8,795in general payments, 2019–2025

Across 231 payments — averaging $38.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • AbbVie$634
  • Merck$356
  • Amgen$354
  • Johnson & Johnson$281
  • Pfizer$263
  • plus $3K from 43 others

What the payments were for

  • Consulting fees$3,50040%
  • Food & beverage$5,00457%
  • Education$2913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,795 in reported general payments places this provider in the 75th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$354,928
Medicare patients
1,081
Services billed
5,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron127$107,483
MyrbetriqMirabegron52$56,724
OrgovyxRelugolix15$40,888
Tamsulosin Hcl1,200$19,551
Finasteride656$7,630
Alfuzosin Hcl ErAlfuzosin Hcl118$3,428
Trospium Chloride ErTrospium Chloride27$3,364
Testosterone31$2,945
Silodosin26$2,718
Dutasteride72$2,673
Potassium Citrate ErPotassium Citrate16$1,327
Cephalexin57$992
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip43$763
Oxybutynin Chloride ErOxybutynin Chloride41$760
Trospium Chloride11$661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$237$148,370142 claims
Astellas Pharma US IncMyrbetriq$145$56,72452 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 156 urology providers in Connecticut.

Other urology in Danbury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →